Overview
CADL market data
Price History
CADL price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for CADL. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
Stifel Initiates Coverage On Candel Therapeutics with Buy Rating, Announces Price Target of $22Benzinga · Jul 13, 2026, 9:53 AM
Candel Therapeutics Starts Pivotal Phase 3 AURORA Study Of Aglatimagene Besadenovec Plus Valacyclovir In Combination With Continued Pembrolizumab In Participants With Metastatic Non-Squamous Non-Small Cell Lung CancerBenzinga · Jun 30, 2026, 12:20 PM
8-K filing — Candel Therapeutics, Inc. (CADL)SEC EDGAR · Jun 16, 2026, 8:23 PM
Candel Therapeutics Announces Lancet Oncology Publication Of Phase 3 Data Showing 30% DFS Improvement For Aglatimagene Besadenovec In Localized Prostate CancerBenzinga · Jun 2, 2026, 12:19 PM
Candel Therapeutics Presents New Results From Extended Follow-Up Of Randomized, Double-Blind, Placebo-Controlled Pivotal Phase 3 Trial Of Aglatimagene Besadenovec In Prostate Cancer At AUA 2026 Annual MeetingBenzinga · May 15, 2026, 8:07 PM
Candel Therapeutics Q1 EPS $(0.14) Beats $(0.34) EstimateBenzinga · May 14, 2026, 12:12 PM